{"id":202099,"name":"CARIS SCIENCE INC","slug":"caris-science-inc","state":"TX","country":"United States of America","description":"Providing precision medicine services to patients battling aggressive cancers.","totalSpending":1320000,"filings":32,"yearlySpending":[{"year":2018,"income":200000},{"year":2019,"income":160000},{"year":2020,"income":160000},{"year":2021,"income":160000},{"year":2022,"income":160000},{"year":2023,"income":160000},{"year":2024,"income":160000},{"year":2025,"income":160000}],"issues":["HCR","MMM","MED","CPT"],"firms":["SPLITOAK STRATEGIES LLC"],"lobbyists":["AMY JENSEN","SARAH EGGE"],"govEntities":["Centers For Medicare and Medicaid Services (CMS)","Food & Drug Administration (FDA)","HOUSE OF REPRESENTATIVES","SENATE","White House Office","Health & Human Services, Dept of (HHS)","Justice, Dept of (DOJ)"],"sampleDescriptions":["Discussion draft by Reps. Bucshon and DeGette to reform the Food & Drug Administration's oversight of diagnostic medical devices and clinical lab services.","Medicare coverage and reimbursement of Next Generation Sequencing in advanced cancer. Finalize PAMA reform of clinical lab reimbursement. Proposed National Coverage Decision on Next Generation Sequenc","FDA oversight of Next Generation Sequencing technology for advanced cancers. Medicare coverage of Next Generation Sequencing technology for advanced cancers. Finalize PAMA reform of Medicare clinical ","FDA oversight of Next Generation Sequencing technology for advanced cancers. Medicare coverage of Next Generation Sequencing technology for advanced cancers. Finalize PAMA reform of Medicare clinical ","Discussion draft by Reps. Bucshon and DeGette to reform the Food & Drug Administration's oversight of diagnostic medical devices and clinical lab services."],"years":[2018,2019,2020,2021,2022,2023,2024,2025]}